Andrea S. Blevins Primeau, PhD, MBA

Patients with cancer were more likely to die from the BA.1 and BA.2 omicron variants of SARS-CoV-2 than from wild-type SARS-CoV-2, data suggest.

Patients with advanced melanoma who receive T-VEC prior to surgery have better long-term outcomes than patients treated with surgery alone, updated data suggest.

A polygenic risk score can predict the risk of second malignant neoplasms in pediatric cancer survivors who were treated with chemotherapy, according to researchers.

The prevalence of TERT promoter mutations among patients with cancer differs by race and sex, a large study suggests.

Prior authorization requirements for oral cancer drugs on Medicare part D formularies have increased in recent years, research suggests.

Treating advanced melanoma with immune checkpoint inhibitors can be safe and effective in patients with concomitant CLL, a study suggests.

Relapse-free survival should not be used as a surrogate for overall survival in cancer trials testing adjuvant immunotherapy, according to researchers.

The number of patients with a prior cancer who have been diagnosed with a new cancer has increased by approximately 15% during a 6-year period, a study suggests.

Biomarkers should be used when selecting patients with cancer for immune checkpoint inhibitor therapy, according to researchers. 

The COVID-19 pandemic caused reductions in cancer diagnoses in 2020 that may pose challenges for interpreting long-term cancer trends.

Patients with cancer with type 2 diabetes may have worse survival outcomes on immune checkpoint inhibitor therapy, a new study suggests.

Combination treatment with MEDI1191 and durvalumab has demonstrated activity in a phase 1 trial of patients with advanced solid tumors.

Neoadjuvant vibostolimab plus pembrolizumab has shown antitumor activity in a phase 1/2 trial of patients with stage IIIB-D melanoma.

Adding an mRNA vaccine to adjuvant treatment with pembrolizumab prolongs relapse-free survival in high-risk melanoma, a phase 2 study suggests.

Patients with MCC may have different sites of disease, stage at diagnosis, and survival outcomes according to their racial or ethnic group.

Adolescent and young adult patients diagnosed with cancer during pregnancy have a higher risk of adverse birth outcomes, a study suggests.

Personalized ctDNA monitoring can predict outcomes during and after treatment in patients with advanced melanoma, a study suggests.

Periadjuvant pembrolizumab may improve outcomes over adjuvant pembrolizumab alone in patients with resectable stage III-IV melanoma, a phase 2 study suggests.

COVID-19 vaccines did not reduce the risk of severe COVID-19 among cancer patients who received radiation, CAR T-cell therapy, or HSCT.

Nivolumab plus relatlimab can produce durable responses in patients with advanced melanoma whose disease progressed on anti-PD-1/PD-L1 regimens.

Patient-reported outcomes in oncology trials are similar whether the trials have open-label or blinded designs, new research suggests.

Roughly half of hospitals accredited by the ACS-CoC failed to disclose the cost of 5 common cancer surgeries, researchers found.

Inpatient treatment with immune checkpoint inhibitors is associated with poor survival outcomes in patients with advanced cancer.

The optimal sequence of treatment for BRAF-mutant melanoma is nivolumab-ipilimumab followed by dabrafenib-trametinib, a study suggests.

Neoadjuvant plus adjuvant pembrolizumab can prolong event-free survival vs adjuvant pembrolizumab alone in resectable melanoma.

Exposure to low-dose methotrexate is associated with an increased risk of melanoma, according to a meta-analysis of 17 studies.

Race and ethnicity were reported in less than 25% of the trials studied.

Researchers sought to determine the impact of body changes on pediatric patients who undergo treatment for AML.